## Coronary Artery Calcium (CAC) Scoring: Navigating Risk Stratification in Familial CAD - A 2025 Update
The landscape of cardiovascular disease prevention is constantly evolving. Recent research, particularly the CAUGHT-CAD trial published in early August 2025, has reignited debate surrounding the role of coronary artery calcium (CAC) scoring in primary prevention, specifically for individuals with an inherited predisposition to coronary artery disease (CAD). While the trial offered valuable data, a nuanced understanding of its methodology and implications is crucial for clinicians and patients alike. this article delves into the intricacies of CAC scoring, its submission in familial CAD, and the critical considerations arising from the CAUGHT-CAD findings.### Understanding Coronary Artery Calcium (CAC) Scoring
CAC scoring is a non-invasive imaging technique utilizing computed tomography (CT) to quantify the amount of calcified plaque in the coronary arteries. This score isn’t simply a measure of blockage; it reflects the *burden* of atherosclerosis – the underlying process of plaque buildup. A higher CAC score generally correlates with a greater risk of future cardiovascular events, such as heart attack or stroke.
Traditionally, CAC scoring has been recommended for asymptomatic individuals at intermediate risk based on traditional risk factors (age, cholesterol, blood pressure, smoking status). However, the presence of a family history of premature CAD significantly alters this risk profile, prompting questions about the optimal timing and application of CAC scoring.
### The CAUGHT-CAD Trial: A Closer Examination
The CAUGHT-CAD trial aimed to determine if utilizing CAC scoring for risk stratification in intermediate-risk patients with familial CAD would lead to a reduction in plaque progression. The study enrolled individuals with a family history of early-onset CAD and assessed their risk using CAC scoring. Those in the intervention group received a CAC score result and were promptly initiated on high-intensity statin therapy (atorvastatin 40mg). The control group received usual care, with statin initiation determined by their physicianS discretion.The results indicated a reduction in plaque progression and improved lipid profiles in the CAC score-informed group. However, a critical point of contention, as highlighted in correspondence to the editor published on August 5th, 2025, is the inherent imbalance in statin exposure between the two groups.
The study design effectively created a scenario where the intervention wasn’t solely *CAC score-informed care*, but rather *high-intensity statin therapy initiated based on CAC score*. This raises the question: was the observed benefit attributable to the CAC score itself, or primarily to the statin medication?
“Consequently, the observed reduction in plaque progression and lipid levels in the CAC score-informed group may have been largely attributable to statin therapy, and it is unclear whether being informed of the CAC score conferred any additional benefit.”
This isn’t to invalidate the trial’s findings entirely. Statins remain a cornerstone of cardiovascular prevention, and their efficacy is well-established. Though, it underscores the importance of rigorous study design and careful interpretation of results.
### Familial CAD and the Role of Proactive Screening
Individuals with a strong family history of premature CAD face a significantly elevated risk compared to the general population. This is due to a complex interplay of genetic predisposition and shared lifestyle factors.
In these cases, a more proactive approach to risk assessment is warranted. CAC scoring can serve as a valuable tool to refine risk stratification *beyond* traditional risk factors. A zero CAC score, for example, is associated with a very low risk of future events, potentially allowing for a more conservative approach to medication. Conversely,a significant CAC score may prompt earlier and more aggressive intervention.
However, it’s crucial to remember that CAC scoring is not a standalone diagnostic test. It should be integrated into a complete risk assessment,considering the patient’s overall